Novartis is already suing a long list of generics producers that aim to bring copycats of the company’s popular heart failure drug Entresto to market. Now, the Swiss pharma itself has become target in a patent infringement lawsuit.
Entresto infringes a co-crystal patent held by the University of Michigan and the University of South Florida, the two institutions alleged in a complaint filed Monday in the U.S. District Court for the Northern District of California.
The universities are seeking a jury trial and damages to compensate for the alleged patent infringement. Since Entresto is a blockbuster that generated $3.55 billion worldwide last year, the damages, if awarded, could wind up being significant.
Entresto is a combination of sacubitril and valsartan. Thanks to an expanded FDA nod in 2021 to treat patients with heart failure with preserved ejection fraction (HFpEF), Entresto saw sales jump 37% at constant currencies in the first half of 2022 to $2.22 billion. Novartis has said the combo therapy could reach $5 billion in peak sales.